{"title":"covid -19后脑毛霉病(由Rhinocladiella mackenzie引起):中东版的covid -19后毛霉病?","authors":"Bhushan Sudhakar Wankhade, Ammar Mohamed Abdel Hadi, Ghaya Zeyad Alrais, Zeyad Faoor Alrais, Ahmad Elzayyat","doi":"10.4103/jgid.jgid_105_22","DOIUrl":null,"url":null,"abstract":"Healthcare‐associated infections (HAIs) are not uncommon after COVID‐19. Kubin et al. reported that the incidence of post‐COVID‐19 HAIs was around 12%.[1] Out of these, 57% were bacterial and 19% were fugal.[2] Although candidemia was the most common fungal infection, the Indian population witnessed the storm of “mucormycosis.”[2] The risk factors and the pathophysiology of post‐COVID‐19 mucormycosis are well described in medical literature.[2] Recently, we came across a case of “cerebral pheohyphomycosis (CH)” after COVID‐19.","PeriodicalId":51581,"journal":{"name":"Journal of Global Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/43/JGID-14-173.PMC9831205.pdf","citationCount":"1","resultStr":"{\"title\":\"Post-COVID-19 Cerebral Pheohyphomycosis due to <i>Rhinocladiella mackenziei</i>: A Middle Eastern Replica of Post-COVID-19 Mucormycosis?\",\"authors\":\"Bhushan Sudhakar Wankhade, Ammar Mohamed Abdel Hadi, Ghaya Zeyad Alrais, Zeyad Faoor Alrais, Ahmad Elzayyat\",\"doi\":\"10.4103/jgid.jgid_105_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Healthcare‐associated infections (HAIs) are not uncommon after COVID‐19. Kubin et al. reported that the incidence of post‐COVID‐19 HAIs was around 12%.[1] Out of these, 57% were bacterial and 19% were fugal.[2] Although candidemia was the most common fungal infection, the Indian population witnessed the storm of “mucormycosis.”[2] The risk factors and the pathophysiology of post‐COVID‐19 mucormycosis are well described in medical literature.[2] Recently, we came across a case of “cerebral pheohyphomycosis (CH)” after COVID‐19.\",\"PeriodicalId\":51581,\"journal\":{\"name\":\"Journal of Global Infectious Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/43/JGID-14-173.PMC9831205.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Global Infectious Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jgid.jgid_105_22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Global Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jgid.jgid_105_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Post-COVID-19 Cerebral Pheohyphomycosis due to Rhinocladiella mackenziei: A Middle Eastern Replica of Post-COVID-19 Mucormycosis?
Healthcare‐associated infections (HAIs) are not uncommon after COVID‐19. Kubin et al. reported that the incidence of post‐COVID‐19 HAIs was around 12%.[1] Out of these, 57% were bacterial and 19% were fugal.[2] Although candidemia was the most common fungal infection, the Indian population witnessed the storm of “mucormycosis.”[2] The risk factors and the pathophysiology of post‐COVID‐19 mucormycosis are well described in medical literature.[2] Recently, we came across a case of “cerebral pheohyphomycosis (CH)” after COVID‐19.
期刊介绍：
JGID encourages research, education and dissemination of knowledge in the field of Infectious Diseases across the world thus promoting translational research by striking a synergy between basic science, clinical medicine and public health. The Journal intends to bring together scientists and academicians in Infectious Diseases to promote translational synergy between Laboratory Science, Clinical Medicine and Public Health. The Journal invites Original Articles, Clinical Investigations, Epidemiological Analysis, Data Protocols, Case Reports, Clinical Photographs, review articles and special commentaries. Students, Residents, Academicians, Public Health experts and scientists are all encouraged to be a part of this initiative by contributing, reviewing and promoting scientific works and science.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
